Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shipo Wu

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Nature Medicine|January 28, 2022
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trialJingxin Li, Lihua Hou, Xiling Guo, et al.
Nature Communications|August 7, 2025
Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trialShipo Wu, Jianying Huang, Busen Wang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 3, 2021
Safety and Immunogenicity of a Recombinant Tetanus Vaccine in Healthy Adults in China: A Randomized, Double-Blind, Dose Escalation, Placebo- and Positive-Controlled, Phase 1/2 TrialXiaowei Xu, Rui Yu, Lanlan Xiao, et al.
Emerging Microbes & Infections|December 12, 2022
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trialLairun Jin, Rong Tang, Shipo Wu, et al.
The Journal of Infectious Diseases|April 5, 2018
Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal ModelsQiang Guo, Jasper Fuk-Woo Chan, Vincent Kwok-Man Poon, et al.
Human Vaccines & Immunotherapeutics|July 15, 2017
Open-label phase I clinical trial of Ad5-EBOV in Africans in ChinaLihua Wu, Zhe Zhang, Hainv Gao, et al.
Nature Communications|August 16, 2020
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challengeShipo Wu, Gongxun Zhong, Jun Zhang, et al.
Signal Transduction and Targeted Therapy|April 28, 2022
Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccinationXiangyang Chi, Yingying Guo, Guanying Zhang, et al.
Plos Pathogens|August 5, 2024
SARS-CoV-2 spike-induced syncytia are senescent and contribute to exacerbated heart failureHuilong Li, Luming Wan, Muyi Liu, et al.
Frontiers in Immunology|October 23, 2023
Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipientsZhe Zhang, Shipo Wu, Yawei Liu, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Nature Medicine|January 28, 2022
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trialJingxin Li, Lihua Hou, Xiling Guo, et al.
Nature Communications|August 7, 2025
Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trialShipo Wu, Jianying Huang, Busen Wang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 3, 2021
Safety and Immunogenicity of a Recombinant Tetanus Vaccine in Healthy Adults in China: A Randomized, Double-Blind, Dose Escalation, Placebo- and Positive-Controlled, Phase 1/2 TrialXiaowei Xu, Rui Yu, Lanlan Xiao, et al.
Emerging Microbes & Infections|December 12, 2022
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trialLairun Jin, Rong Tang, Shipo Wu, et al.
The Journal of Infectious Diseases|April 5, 2018
Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal ModelsQiang Guo, Jasper Fuk-Woo Chan, Vincent Kwok-Man Poon, et al.
Human Vaccines & Immunotherapeutics|July 15, 2017
Open-label phase I clinical trial of Ad5-EBOV in Africans in ChinaLihua Wu, Zhe Zhang, Hainv Gao, et al.
Nature Communications|August 16, 2020
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challengeShipo Wu, Gongxun Zhong, Jun Zhang, et al.
Signal Transduction and Targeted Therapy|April 28, 2022
Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccinationXiangyang Chi, Yingying Guo, Guanying Zhang, et al.
Plos Pathogens|August 5, 2024
SARS-CoV-2 spike-induced syncytia are senescent and contribute to exacerbated heart failureHuilong Li, Luming Wan, Muyi Liu, et al.
Frontiers in Immunology|October 23, 2023
Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipientsZhe Zhang, Shipo Wu, Yawei Liu, et al.
Pageof 6